Study of Ocular Therapeutix’s Dextenza

Date:
Business Wire: March 15, 2017 – BEDFORD, MA, U.S.A. – Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive results of a patient…